Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

539 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Immunopathogenic mechanisms of systemic autoimmune disease.
Wahren-Herlenius M, Dörner T. Wahren-Herlenius M, et al. Among authors: dorner t. Lancet. 2013 Aug 31;382(9894):819-31. doi: 10.1016/S0140-6736(13)60954-X. Lancet. 2013. PMID: 23993191 Review.
Type 1 interferon produced by innate immune cells has a central role in systemic autoimmunity and activates B cells and T cells. ...
Type 1 interferon produced by innate immune cells has a central role in systemic autoimmunity and activates B cells and T cells. ...
[Cytometric analyses in systemic autoimmune diseases].
Dörner T, Odendahl M, Radbruch A. Dörner T, et al. Z Rheumatol. 2002 Aug;61(4):389-95. doi: 10.1007/s00393-002-0433-3. Z Rheumatol. 2002. PMID: 12426844 Review. German.
Mechanisms of B cell autoimmunity in SLE.
Dörner T, Giesecke C, Lipsky PE. Dörner T, et al. Arthritis Res Ther. 2011;13(5):243. doi: 10.1186/ar3433. Epub 2011 Oct 27. Arthritis Res Ther. 2011. PMID: 22078750 Free PMC article. Review.
Of importance, new information has made it possible to distinguish between the contribution played by abnormalities in central checkpoints that could lead to a pre-immune repertoire enriched in autoreactive B cells, on the one hand, and the possibility that autoimmunity arises in …
Of importance, new information has made it possible to distinguish between the contribution played by abnormalities in central checkpoints t …
CD22 and autoimmune disease.
Dörner T, Shock A, Smith KG. Dörner T, et al. Int Rev Immunol. 2012 Oct;31(5):363-78. doi: 10.3109/08830185.2012.709890. Int Rev Immunol. 2012. PMID: 23083346 Review.
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.
van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrøm K, Aringer M, Bootsma H, Boumpas D, Bruce IN, Cervera R, Clarke A, Costedoat-Chalumeau N, Czirják L, Derksen R, Dörner T, Gordon C, Graninger W, Houssiau F, Inanc M, Jacobsen S, Jayne D, Jedryka-Goral A, Levitsky A, Levy R, Mariette X, Morand E, Navarra S, Neumann I, Rahman A, Rovensky J, Smolen J, Vasconcelos C, Voskuyl A, Voss A, Zakharova H, Zoma A, Schneider M. van Vollenhoven RF, et al. Among authors: dorner t. Ann Rheum Dis. 2014 Jun;73(6):958-67. doi: 10.1136/annrheumdis-2013-205139. Epub 2014 Apr 16. Ann Rheum Dis. 2014. PMID: 24739325
Sickness absence due to back pain or depressive episode and the risk of all-cause and diagnosis-specific disability pension: A Swedish cohort study of 4,823,069 individuals.
Dorner TE, Alexanderson K, Svedberg P, Ropponen A, Stein KV, Mittendorfer-Rutz E. Dorner TE, et al. Eur J Pain. 2015 Oct;19(9):1308-20. doi: 10.1002/ejp.661. Epub 2015 Feb 20. Eur J Pain. 2015. PMID: 25703233
Cytokine-producing B cells: a translational view on their roles in human and mouse autoimmune diseases.
Lino AC, Dörner T, Bar-Or A, Fillatreau S. Lino AC, et al. Among authors: dorner t. Immunol Rev. 2016 Jan;269(1):130-44. doi: 10.1111/imr.12374. Immunol Rev. 2016. PMID: 26683150 Review.
Off-label use of rituximab for systemic lupus erythematosus in Europe.
Rydén-Aulin M, Boumpas D, Bultink I, Callejas Rubio JL, Caminal-Montero L, Castro A, Colodro Ruiz A, Doria A, Dörner T, Gonzalez-Echavarri C, Gremese E, Houssiau FA, Huizinga T, Inanç M, Isenberg D, Iuliano A, Jacobsen S, Jimenéz-Alonso J, Kovács L, Mariette X, Mosca M, Nived O, Oristrell J, Ramos-Casals M, Rascón J, Ruiz-Irastorza G, Sáez-Comet L, Salvador Cervelló G, Sebastiani GD, Squatrito D, Szücs G, Voskuyl A, van Vollenhoven R. Rydén-Aulin M, et al. Among authors: dorner t. Lupus Sci Med. 2016 Sep 6;3(1):e000163. doi: 10.1136/lupus-2016-000163. eCollection 2016. Lupus Sci Med. 2016. PMID: 27651920 Free PMC article.
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, Dörner T, Cardiel MH, Bruce IN, Gomez E, Carmack T, DeLozier AM, Janes JM, Linnik MD, de Bono S, Silk ME, Hoffman RW. Wallace DJ, et al. Among authors: dorner t. Lancet. 2018 Jul 21;392(10143):222-231. doi: 10.1016/S0140-6736(18)31363-1. Lancet. 2018. PMID: 30043749 Clinical Trial.
Novel paradigms in systemic lupus erythematosus.
Dörner T, Furie R. Dörner T, et al. Lancet. 2019 Jun 8;393(10188):2344-2358. doi: 10.1016/S0140-6736(19)30546-X. Epub 2019 Jun 6. Lancet. 2019. PMID: 31180031 Review.
539 results
Jump to page
Feedback